ImClone Systems 2007 Oncology Product Development	Pre- Clinical	IND Filing	Phase I	Phase II	Phase III	FDA Appr- oval	Phase IV
GROWTH FACTOR BLOCKERS
Erbitux®
TARGET: EGFR INDICATIONS:
Irinotecan refractory or intolerant metastatic colorectal cancer*
Earlier stage colorectal cancer
Non-small cell lung cancer
Head & neck cancer
Pancreatic cancer
Other
IMC-11F8
TARGET: EGFR INDICATION: Solid tumors
IMC-A12
TARGET: IGF-1R INDICATION: Solid tumors
IMC-18F1
TARGET: VEGFR-1 INDICATION: Breast, CRC
IMC-3G3
TARGET: PDGFRα INDICATION: Prostate, breast, ovarian
ANGIOGENESIS INHIBITORS
IMC-1121b
TARGET: VEGFR-2/KDR INDICATION: Solid and liquid tumors

*Please visit www.Erbitux.com for full U.S. prescribing information, including important safety information